Dow Jones

40 211,72

0,53%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Summit Therapeutics Inc (SMMT)
Summit Therapeutics Inc (SMMT) Actualités

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:SMMT

<< Précédent 1 2 3 4 5 6 7 8 9 10 11 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
09/01/2018	13h00	GlobeNewswire Inc.	Summit Therapeutics to Present at the Biotech Showcase	NASDAQ:SMMT	Summit Therapeutics Inc
03/01/2018	19h47	Edgar (US Regulatory)	Confidential Treatment Order (ct Order)	NASDAQ:SMMT	Summit Therapeutics Inc
26/12/2017	13h27	Edgar (US Regulatory)	Report of Foreign Issuer (6-k)	NASDAQ:SMMT	Summit Therapeutics Inc
23/12/2017	22h00	GlobeNewswire Inc.	Summit Obtains Innovative Antibiotic Discovery and Development Platform Through Acquisition of Discuva Ltd	NASDAQ:SMMT	Summit Therapeutics Inc
06/12/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics Reports Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 and Operational Pro...	NASDAQ:SMMT	Summit Therapeutics Inc
06/12/2017	08h00	GlobeNewswire Inc.	Santhera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy ...	NASDAQ:SMMT	Summit Therapeutics Inc
04/12/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 201...	NASDAQ:SMMT	Summit Therapeutics Inc
22/11/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Participate in Upcoming Investor Conferences	NASDAQ:SMMT	Summit Therapeutics Inc
20/11/2017	13h00	GlobeNewswire Inc.	Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical Trial	NASDAQ:SMMT	Summit Therapeutics Inc
09/11/2017	13h00	GlobeNewswire Inc.	Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International ...	NASDAQ:SMMT	Summit Therapeutics Inc
06/11/2017	15h29	GlobeNewswire Inc.	Summit Announces Signing of Revenue Sharing Agreement With the Wellcome Trust for CDI Antibiotic Ridinilazole	NASDAQ:SMMT	Summit Therapeutics Inc
25/10/2017	15h00	GlobeNewswire Inc.	Grant of Share Options to Directors, PDMRs and Employees and Grant of Restricted Stock Units to Non-Executive Directors	NASDAQ:SMMT	Summit Therapeutics Inc
09/10/2017	13h00	GlobeNewswire Inc.	Summit Highlights Microbiome Preservation During Ridinilazole Treatment in Exploratory Phase 2 Clinical Trial at ID Week 2017...	NASDAQ:SMMT	Summit Therapeutics Inc
04/10/2017	13h00	GlobeNewswire Inc.	Summit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd ...	NASDAQ:SMMT	Summit Therapeutics Inc
02/10/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Host R&D Day 11 October 2017	NASDAQ:SMMT	Summit Therapeutics Inc
25/09/2017	13h00	GlobeNewswire Inc.	Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne...	NASDAQ:SMMT	Summit Therapeutics Inc
20/09/2017	19h06	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:SMMT	Summit Therapeutics Inc
15/09/2017	19h31	GlobeNewswire Inc.	Summit Therapeutics Announces Exercise of Underwriters’ Over-Allotment Option	NASDAQ:SMMT	Summit Therapeutics Inc
14/09/2017	23h21	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:SMMT	Summit Therapeutics Inc
14/09/2017	05h03	GlobeNewswire Inc.	Summit Therapeutics Announces Pricing of Public Offering of 1,459,000 American Depositary Shares	NASDAQ:SMMT	Summit Therapeutics Inc
13/09/2017	22h35	GlobeNewswire Inc.	Summit Therapeutics Announces Proposed Public Offering of $15.0 Million of American Depositary Shares	NASDAQ:SMMT	Summit Therapeutics Inc
11/09/2017	13h00	GlobeNewswire Inc.	Summit Awarded BARDA Contract Worth Up to $62 Million to Support the Development of Ridinilazole for the Treatment of C. diff...	NASDAQ:SMMT	Summit Therapeutics Inc
05/09/2017	13h00	GlobeNewswire Inc.	Summit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Select...	NASDAQ:SMMT	Summit Therapeutics Inc
31/08/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics Reports Financial Results for the Second Quarter and Half Year Ended 31 July 2017 and Operational Progre...	NASDAQ:SMMT	Summit Therapeutics Inc
25/08/2017	15h30	GlobeNewswire Inc.	Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2017 on 31 August 2017	NASDAQ:SMMT	Summit Therapeutics Inc
03/08/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Present at the Canaccord Genuity Growth Conference	NASDAQ:SMMT	Summit Therapeutics Inc
22/06/2017	23h44	Dow Jones News	ADRs End Higher; Pharmaceuticals Trade Actively	NASDAQ:SMMT	Summit Therapeutics Inc
22/06/2017	13h00	GlobeNewswire Inc.	Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress	NASDAQ:SMMT	Summit Therapeutics Inc
15/06/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics to Participate in JMP Securities Life Sciences Conference	NASDAQ:SMMT	Summit Therapeutics Inc
14/06/2017	13h00	GlobeNewswire Inc.	Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress	NASDAQ:SMMT	Summit Therapeutics Inc